has selected XIFAXAN ® (rifaximin) 550 mg tablets as one of the medicines for the second round of negotiation as part of the Inflation Reduction Act with an initial price applicability in 2027 of ...

Rifaximin is a semi-synthetic derivative of rifampin and acts by binding to the beta-subunit of bacterial DNA-dependent RNA polymerase blocking one of the steps in transcription. This results in ...

Bausch Health (BHC) Companies and Salix Pharmaceuticals acknowledged that the Centers for Medicare and Medicaid Services has selected XIFAXAN 550 mg tablets as one of the medicines for the second ...

All subjects underwent lactulose/methane breath test (LBT) to assess SIBO before and one month after the treatment with Rifaximin 600 mg daily. All IBS pts filled out a Visual Analogic Scale (VAS ...

(rifaximin) 550 mg tablets as one of the medicines for the second round of negotiation as part of the Inflation Reduction Act with an initial price applicability in 2027 of the Drug Price ...